ECMO to rescue Lung Injury in severe ARDS
EOLIA is a multicenter, international, randomized, controlled trial run by the REVA network and endorsed by the International ECMO Network. The study hypothesizes that ECMO, instituted early after the diagnosis of very severe ARDS (P:F < 80), would lower the morbidity and mortality associated with this syndrome.
ImmunoDeficiency and ECMO for Acute respiratory failure
This study will provide, for the first time, detailed descriptive data on the characteristics, the complication and the outcome of adult’s immunocompromised patients receiving ECMO for ARDS. This study is closed